Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 9
2005 8
2006 7
2007 9
2008 5
2009 8
2010 5
2011 5
2012 10
2013 12
2014 16
2015 13
2016 15
2017 13
2018 16
2019 10
2020 6
2021 14
2022 11
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.
Zwirner S, Abu Rmilah AA, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou AA, Schuette S, Haag M, Selig R, Li K, Zhou W, Nelson E, Poso A, Chen H, Amiot B, Jia Y, Minshew A, Michalak G, Cui W, Rist E, Longerich T, Jung B, Felgendreff P, Trompak O, Premsrirut PK, Gries K, Muerdter TE, Heinkele G, Wuestefeld T, Shapiro D, Weissbach M, Koenigsrainer A, Sipos B, Ab E, Zacarias MO, Theisgen S, Gruenheit N, Biskup S, Schwab M, Albrecht W, Laufer S, Nyberg S, Zender L. Zwirner S, et al. Among authors: sipos b. Cell. 2024 Mar 28;187(7):1666-1684.e26. doi: 10.1016/j.cell.2024.02.023. Epub 2024 Mar 14. Cell. 2024. PMID: 38490194 Free PMC article. Clinical Trial.
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
Trautwein NF, Hinterleitner C, Kiefer LS, Singer S, Mattern S, Schwenck J, Reischl G, Sipos B, Lauer UM, Dittmann H, Zender L, la Fougère C, Hinterleitner M. Trautwein NF, et al. Among authors: sipos b. Clin Nucl Med. 2024 Mar 1;49(3):207-214. doi: 10.1097/RLU.0000000000005006. Epub 2024 Jan 23. Clin Nucl Med. 2024. PMID: 38271237
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M, Pfeiffer R, Trautwein NF, Sipos B, Singer S, Nadalin S, Königsrainer A, Lauer UM, la Fougère C, Zender L, Hinterleitner C. Hinterleitner M, et al. Among authors: sipos b. Front Endocrinol (Lausanne). 2024 Jan 8;14:1285529. doi: 10.3389/fendo.2023.1285529. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260136 Free PMC article.
[Multiple neuroendocrine tumors of the pancreas].
Sipos B. Sipos B. Pathologie (Heidelb). 2024 Feb;45(1):28-34. doi: 10.1007/s00292-023-01289-z. Epub 2024 Jan 5. Pathologie (Heidelb). 2024. PMID: 38180510 Review. German.
193 results